Allovir Earnings Estimate

ALVR Stock  USD 9.28  0.28  3.11%   
The next projected EPS of Allovir is estimated to be -0.105 with future projections ranging from a low of -0.105 to a high of -0.105. Allovir's most recent 12-month trailing earnings per share (EPS TTM) is at -0.9. Please be aware that the consensus of earnings estimates for Allovir is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Allovir is projected to generate -0.105 in earnings per share on the 31st of December 2024. Allovir earnings estimates show analyst consensus about projected Allovir EPS (Earning Per Share). It derives the highest and the lowest estimates based on Allovir's historical volatility. Many public companies, such as Allovir, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Allovir's earnings estimates, investors can diagnose different trends across Allovir's analyst sentiment over time as well as compare current estimates against different timeframes. As of 01/19/2025, Gross Profit is likely to drop to about (376.1 K). In addition to that, Pretax Profit Margin is likely to grow to -157.84
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allovir. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
To learn how to invest in Allovir Stock, please use our How to Invest in Allovir guide.

Allovir Earnings Estimation Breakdown

The calculation of Allovir's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Allovir is estimated to be -0.105 with the future projection ranging from a low of -0.105 to a high of -0.105. Please be aware that this consensus of annual earnings estimates for Allovir is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-0.04
-0.1
Lowest
Expected EPS
-0.105
-0.1
Highest

Allovir Earnings Projection Consensus

Suppose the current estimates of Allovir's value are higher than the current market price of the Allovir stock. In this case, investors may conclude that Allovir is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Allovir's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of December 2024Current EPS (TTM)
166.38%
-0.0358
-0.105
-0.9

Allovir Earnings per Share Projection vs Actual

Actual Earning per Share of Allovir refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Allovir predict the company's earnings will be in the future. The higher the earnings per share of Allovir, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Allovir Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Allovir, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Allovir should always be considered in relation to other companies to make a more educated investment decision.

Allovir Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Allovir's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-01
2024-09-30-0.09-0.03580.054260 
2024-08-05
2024-06-30-0.1-0.050.0550 
2024-05-13
2024-03-31-0.16-0.26-0.162 
2024-03-15
2023-12-31-0.43-0.360.0716 
2023-11-02
2023-09-30-0.42-0.390.03
2023-08-03
2023-06-30-0.45-0.48-0.03
2023-05-04
2023-03-31-0.46-0.440.02
2023-02-15
2022-12-31-0.54-0.370.1731 
2022-11-03
2022-09-30-0.53-0.50.03
2022-08-04
2022-06-30-0.73-0.690.04
2022-05-05
2022-03-31-0.8-0.690.1113 
2022-02-10
2021-12-31-0.81-0.92-0.1113 
2021-11-05
2021-09-30-0.55-0.72-0.1730 
2021-08-06
2021-06-30-0.49-0.6-0.1122 
2021-05-06
2021-03-31-0.4-0.5-0.125 
2021-02-11
2020-12-31-0.42-0.340.0819 
2020-11-10
2020-09-30-0.3-0.58-0.2893 
2020-09-02
2020-06-30-0.31-0.040.2787 
2020-06-03
2020-03-310-4.21-4.21

About Allovir Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Allovir earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Allovir estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Allovir fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-590.6 M-561 M
Retained Earnings Total Equity-419.2 M-440.2 M
Earnings Yield(3.10)(2.94)
Price Earnings Ratio(0.33)(0.35)
Price Earnings To Growth Ratio 0.02  0.02 

Pair Trading with Allovir

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allovir position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will appreciate offsetting losses from the drop in the long position's value.

Moving together with Allovir Stock

  0.65EQ EquilliumPairCorr
  0.79ME 23Andme HoldingPairCorr
  0.87VALN Valneva SE ADRPairCorr

Moving against Allovir Stock

  0.85VCEL Vericel Corp OrdPairCorr
  0.8VCYT Veracyte Potential GrowthPairCorr
  0.78DRTS Alpha Tau MedicalPairCorr
  0.72DMAC DiaMedica TherapeuticsPairCorr
  0.63CDIOW Cardio DiagnosticsPairCorr
The ability to find closely correlated positions to Allovir could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allovir when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allovir - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allovir to buy it.
The correlation of Allovir is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allovir moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allovir moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allovir can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Allovir Stock Analysis

When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.